Key result
Loss-of-function variants in ANGPTL3 are associated with familial combined hypolipidemia, characterized by marked reduction of all plasma lipoproteins.
ANGPTL3 is identified as a key regulator of lipid and glucose metabolism, making it a promising therapeutic target for reducing cardio-metabolic risk.
Answers are grounded in this paper and cite their sources.
Supports ANGPTL3 as therapeutic target; leaves open cardiovascular benefit confirmation in randomized trials.
PURPOSE OF REVIEW: Cumulating evidence are revealing roles of angiopoietin-like proteins (ANGPTLs) in lipid, glucose, and energy metabolism. In this review, we discuss the recent developments in understanding the specific role in metabolic processes of the liver-derived ANGPTL3. RECENT FINDINGS: Several groups have reported clinical and metabolic characterization of individuals with loss-of-function variants in ANGPTL3 showing familial combined hypolipidemia, a syndrome characterized by marked reduction of all plasma lipoproteins. Their findings indicate that in humans, ANGPTL3 has a broader action on apoB and apoA-I-containing lipoproteins, as well as on free fatty acid and adipose tissue metabolism. SUMMARY: The identification of loss-of-function ANGPTL3 mutation is shedding light on a possible role of ANGPTL3 at the crossroads of lipoproteins, fatty acids, and glucose metabolism, thus making ANGPTL3 an attractive protein to target the cardio-metabolic risk.
No takes yet. Share an insight, caveat, or question.
Arca et al. (2013) conducted a review in Familial combined hypolipidemia. ANGPTL3 loss-of-function variants was evaluated. Loss-of-function variants in ANGPTL3 are associated with familial combined hypolipidemia, characterized by marked reduction of all plasma lipoproteins.
Synapse has enriched 10 related papers. Consider them for comparative context: